Interaction Between Vitamin D and Interleukin 6 on Slow Gait Speed: 6-Year Follow-up Data of Older Adults From InCHIANTI.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this observational study publication.

Whereas the independent effects of biomarkers, including 25-hydroxy vitamin D (25(OH)D), insulin-like growth factor 1, C-reactive protein, and interleukin 6 (IL-6), on gait speed in older adults have been evaluated, their joint effects on gait speed are not well understood.

Who Took Part

The age groups tagged for this paper are older adults and people over 80, both men and women.

Study subjects aged at least 65 at baseline (N = 970) were enrolled in the population-based Invecchiare in Chianti (InCHIANTI) study from 1998 to 2000 and were followed up at 3 and 6 years.

How the Study Was Run

All above biomarkers and gait speed data were measured at each of the three time points.

Further investigation was conducted for interactions between high IL-6 (≥.87 pg/mL) and other biomarkers focusing on low 25(OH)D (<20 ng/mL).

What Was Measured

Whereas the independent effects of biomarkers, including 25-hydroxy vitamin D (25(OH)D), insulin-like growth factor 1, C-reactive protein, and interleukin 6 (IL-6), on gait speed in older adults have been evaluated, their joint effects on gait speed are not well understood.

The subject headings attached to it are Biomarkers, C-Reactive Protein, Gait, Insulin-Like Growth Factor I, Interleukin-6, Vitamin D and Vitamin D Deficiency.

Author keywords: Gait Speed, IL-6 and Interaction.

What This Means in Plain Language

This is an observational study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (The journals of gerontology. Series A, Biological sciences and medical sciences), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.